Christophe Caux

List of Publications by Year
in descending order

138	22,178	20817 60	15732 125
papers	citations	h-index	g-index

149	149	149	22495
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Science Advances, 2022, 8, eabj3671.	10.3	38
2	<scp>HERVs</scp> characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. American Journal of Hematology, 2022, 97, 1200-1214.	4.1	8
3	Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?. Cancer Immunology Research, 2022, 10, 918-918.	3.4	1
4	Type 1 conventional dendritic cells and interferons are required for spontaneous CD4⁺ and CD8⁺ Tâ€cell protective responses to breast cancer. Clinical and Translational Immunology, 2021, 10, e1305.	3.8	35
5	Recruitment and Expansion of Tregs Cells in the Tumor Environmentâ€"How to Target Them?. Cancers, 2021, 13, 1850.	3.7	38
6	Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial. BMC Cancer, 2020, 20, 622.	2.6	5
7	CD163⁺ tumorâ€associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clinical and Translational Immunology, 2020, 9, e1108.	3.8	47
8	Repurposing infectious disease vaccines for intratumoral immunotherapy. , 2020, 8, e000443.		20
9	IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Science Immunology, 2020, 5, .	11.9	86
10	Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses. Cancers, 2019, 11, 1082.	3.7	36
11	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Science Translational Medicine, 2019, 11, .	12.4	49
12	Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production. Journal of Clinical Medicine, 2019, 8, 1859.	2.4	4
13	Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Frontiers in Immunology, 2019, 10, 2155.	4.8	110
14	Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology, 2019, 10, 168.	4.8	733
15	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Frontiers in Immunology, 2019, 10, 925.	4.8	288
16	A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. OncoImmunology, 2019, 8, e1596005.	4.6	18
17	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. , 2019, 7, 85.		175
18	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. Cancer Immunology, Immunotherapy, 2019, 68, 467-478.	4.2	27

#	Article	IF	Citations
19	Neoepitopes-based vaccines: challenges and perspectives. European Journal of Cancer, 2019, 108, 55-60.	2.8	20
20	Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathologica, 2018, 135, 569-579.	7.7	73
21	Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. Cancer Research, 2018, 78, 3604-3618.	0.9	53
22	MDR1 in immunity: friend or foe?. OncoImmunology, 2018, 7, e1499388.	4.6	36
23	MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10404-10409.	7.1	14
24	CD73 expression and clinical significance in human metastatic melanoma. Oncotarget, 2018, 9, 26659-26669.	1.8	39
25	Description of the immune microenvironment of chondrosarcoma and contribution to progression. OncoImmunology, 2017, 6, e1265716.	4.6	26
26	BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. Nature Communications, 2017, 8, 913.	12.8	52
27	Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance. Trends in Cancer, 2017, 3, 491-505.	7.4	32
28	Abstract B55: The alarmin IL-33 is expressed in breast cancer: An emerging role in breast cancer immunity via the activation of NK cells?. , 2017, , .		0
29	Abstract A61: Human BDCA3high dendritic cells infiltrate breast and ovarian tumors but are functionally altered. , 2017, , .		0
30	A Milestone Review on How Macrophages Affect Tumor Growth. Cancer Research, 2016, 76, 6439-6442.	0.9	75
31	Cancer-Associated Tertiary Lymphoid Structures, from Basic Knowledge Toward Therapeutic Target in Clinic. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 99-125.	0.1	0
32	Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy. Cancer Research, 2016, 76, 4648-4660.	0.9	65
33	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. OncoImmunology, 2016, 5, e1091146.	4.6	66
34	TGF-Î² inhibits the activation and functions of NK cells by repressing the mTOR pathway. Science Signaling, 2016, 9, ra19.	3.6	453
35	Abstract 2320: CD70 immune checkpoint ligand is associated with the epithelial-to-mesenchymal transition in non-small cell lung cancer. , 2016, , .		2
36	Abstract 2344: Discovery and characterization of new original blocking antibodies targeting the CD73 immune checkpoint for cancer immunotherapy. Cancer Research, 2016, 76, 2344-2344.	0.9	3

#	Article	IF	Citations
37	Abstract 2338: CD39+ Treg cooperate with a CD73-expressing Th1/Th17 subset for Adenosine-mediated immunosuppression in human breast tumors. , 2016, , .		0
38	In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. Journal of Immunology Research, 2015, 2015, 1-13.	2.2	17
39	Breast Cancer Cellâ€"Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Research, 2015, 75, 2775-2787.	0.9	49
40	Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response. Stem Cell Reports, 2015, 4, 239-254.	4.8	54
41	Paradigm shift in oncology: targeting the immune system rather than cancer cells. Mutagenesis, 2015, 30, 205-211.	2.6	46
42	PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulatorâ€"dependent autoimmunity. Journal of Allergy and Clinical Immunology, 2015, 135, 1578-1588.e5.	2.9	84
43	Human natural killer cells promote crossâ€presentation of tumor cellâ€derived antigens by dendritic cells. International Journal of Cancer, 2015, 136, 1085-1094.	5.1	55
44	Follicular Lymphoma B Cells Generate Functional Regulatory T Cells Via ICOS/ICOSL Pathway and Are Inhibited By Intratumoral Tregs. Blood, 2015, 126, 5018-5018.	1.4	0
45	Human XCR1+ Dendritic Cells Derived In Vitro from CD34+ Progenitors Closely Resemble Blood Dendritic Cells, Including Their Adjuvant Responsiveness, Contrary to Monocyte-Derived Dendritic Cells. Journal of Immunology, 2014, 193, 1622-1635.	0.8	129
46	Intratumoral Immunization: A New Paradigm for Cancer Therapy. Clinical Cancer Research, 2014, 20, 1747-1756.	7.0	191
47	TLR9 Transcriptional Regulation in Response to Double-Stranded DNA Viruses. Journal of Immunology, 2014, 193, 3398-3408.	0.8	8
48	ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progressionin metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 3033-3033.	1.6	1
49	Abstract 2574: Interleukin-7 (CYT107) treatment in lymphopenic 1st line metastatic breast carcinoma patients treated with chemotherapy regimen (Capecitabine) favors the restoration of T-cell subsets number. , 2014, , .		0
50	Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients. , 2014, , .		0
51	Abstract 1109: The antimicrobial peptide LL37 activates plasmacytoid dendritic cells in breast cancer. , 2014, , .		0
52	Abstract LB-253: A comprehensive evaluation of immune checkpoints ligands (ICPLs) in more than 1,000 cancer cell lines (CCLs) identifies specific expression patterns. , 2014, , .		0
53	Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Targeted Oncology, 2013, 8, 261-269.	3.6	10
54	Breast cancerâ€derived transforming growth factorâ€Î²2 and tumor necrosis factorâ€Î± compromise interferonâ€Î± production by tumorâ€associated plasmacytoid dendritic cells. International Journal of Cancer, 2013, 133, 771-778.	5.1	80

#	Article	IF	Citations
55	Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment. Cancer Research, 2013, 73, 4629-4640.	0.9	164
56	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. European Journal of Cancer, 2013, 49, 1673-1682.	2.8	42
57	CD4 lymphopenia to identify end-of-life metastatic cancer patients. European Journal of Cancer, 2013, 49, 1080-1089.	2.8	31
58	ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4⁺T cells by plasmacytoid dendritic cells. OncoImmunology, 2013, 2, e23185.	4.6	61
59	Plasmacytoid dendritic cells deficient in IFNÎ± production promote the amplification of FOXP3⁺regulatory T cells and are associated with poor prognosis in breast cancer patients. OncoImmunology, 2013, 2, e22338.	4.6	46
60	Abstract A22: Overcoming therapeutic MAb resistance in agressive HER2-positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells.. , 2013, , .		0
61	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology, 2012, 1, 380-382.	4.6	114
62	Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. OncoImmunology, 2012, 1, 759-761.	4.6	25
63	ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells. Cancer Research, 2012, 72, 6130-6141.	0.9	184
64	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. OncoImmunology, 2012, 1, 432-440.	4.6	102
65	Combined targeted and immunotherapy: the future of personalized medicine. Blood, 2012, 120, 4454-4455.	1.4	6
66	Impaired IFN-Î± Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Research, 2012, 72, 5188-5197.	0.9	285
67	Targeting pattern recognition receptors in cancer immunotherapy. Targeted Oncology, 2012, 7, 29-54.	3.6	117
68	Targeting regulatory T cells. Targeted Oncology, 2012, 7, 15-28.	3.6	67
69	Recent successes of cancer immunotherapy: a new dimension in personalized medicine?. Targeted Oncology, 2012, 7, 1-2.	3.6	5
70	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. Cancer Research, 2011, 71, 5423-5434.	0.9	200
71	CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood, 2011, 118, 5130-5140.	1.4	42
72	Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer, 2011, 11, 213.	2.6	31

#	Article	IF	Citations
73	CpG Promotes Cross-Presentation of Dead Cell-Associated Antigens by Pre-CD8Î±+ Dendritic Cells. Journal of Immunology, 2011, 186, 1503-1511.	0.8	50
74	Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells. Cancer Research, 2011, 71, 6143-6152.	0.9	100
75	TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like Receptor on Human NK Cells Are Both Mandatory for Production of IFN-Î³ in Response to Double-Stranded RNA. Journal of Immunology, 2010, 185, 2080-2088.	0.8	88
76	Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends in Immunology, 2010, 31, 391-397.	6.8	107
77	Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome. Cancer Research, 2009, 69, 7895-7898.	0.9	99
78	High diversity of the immune repertoire in humanized NOD.SCID.Î³c^{â^'/â^'} mice. European Journal of Immunology, 2009, 39, 2136-2145.	2.9	52
79	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Research, 2009, 69, 2000-2009.	0.9	617
80	P20. Autotaxin promotes metastasis dissemination of breast cancer cells. Cancer Treatment Reviews, 2008, 34, 20-21.	7.7	0
81	Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8047-8052.	7.1	69
82	The Class 6 Semaphorin SEMA6A Is Induced by Interferon-Î³ and Defines an Activation Status of Langerhans Cells Observed in Pathological Situations. American Journal of Pathology, 2006, 168, 453-465.	3.8	19
83	Dendritic Cells Rapidly Recruited into Epithelial Tissues via CCR6/CCL20 Are Responsible for CD8+ T Cell Crosspriming In Vivo. Immunity, 2006, 24, 191-201.	14.3	336
84	Human Langerhans Cells Express a Specific TLR Profile and Differentially Respond to Viruses and Gram-Positive Bacteria. Journal of Immunology, 2006, 177, 7959-7967.	0.8	231
85	Fc receptor Î³-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. Blood, 2005, 105, 3623-3632.	1.4	37
86	MIPâ€3Î±/CCL20 in Renal Transplantation and Its Possible Involvement as Dendritic Cell Chemoattractant in Allograft Rejection. American Journal of Transplantation, 2005, 5, 2114-2125.	4.7	38
87	Recognition of Double-stranded RNA by Human Toll-like Receptor 3 and Downstream Receptor Signaling Requires Multimerization and an Acidic pH. Journal of Biological Chemistry, 2005, 280, 38133-38145.	3.4	225
88	Distinct and Overlapping Roles of Interleukin-10 and CD25+ Regulatory T Cells in the Inhibition of Antitumor CD8 T-Cell Responses. Cancer Research, 2005, 65, 8479-8486.	0.9	66
89	CCL1-CCR8 Interactions: An Axis Mediating the Recruitment of T Cells and Langerhans-Type Dendritic Cells to Sites of Atopic Skin Inflammation. Journal of Immunology, 2005, 174, 5082-5091.	0.8	194
90	Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-Î³ and Th1 chemokine production. Journal of Leukocyte Biology, 2005, 78, 954-966.	3.3	27

#	Article	IF	Citations
91	Critical Role of ITIM-Bearing FcÎ³R on DCs in the Capture and Presentation of Native Antigen to B Cells. Immunity, 2005, 23, 463-464.	14.3	8
92	A type I interferon autocrineâ€“paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. Journal of Experimental Medicine, 2005, 201, 1435-1446.	8.5	481
93	Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86?Langerin- and CD1a+CD86+Langerin+ phenotypes. International Journal of Cancer, 2004, 110, 710-720.	5.1	50
94	The Inducible CXCR3 Ligands Control Plasmacytoid Dendritic Cell Responsiveness to the Constitutive Chemokine Stromal Cellâ€“derived Factor 1 (SDF-1)/CXCL12. Journal of Experimental Medicine, 2003, 198, 823-830.	8.5	216
95	Pharmacological Analysis of Calcium Responses Mediated by the Human A3 Adenosine Receptor in Monocyte-Derived Dendritic Cells and Recombinant Cells. Molecular Pharmacology, 2003, 63, 342-350.	2.3	57
96	Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin. Blood, 2003, 102, 4431-4440.	1.4	60
97	Corticosteroids Prevent Generation of CD34+-Derived Dermal Dendritic Cells But Do Not Inhibit Langerhans Cell Development. Journal of Immunology, 2002, 168, 6181-6188.	0.8	63
98	Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Antiâ€“Interleukin 10 Receptor Antibody. Journal of Experimental Medicine, 2002, 196, 541-549.	8.5	322
99	Isolation and propagation of human dendritic cells. Methods in Microbiology, 2002, 32, 591-620.	0.8	1
100	REGULATION OF DENDRITIC CELL RECRUITMENT BY CHEMOKINES. Transplantation, 2002, 73, S7-S11.	1.0	121
101	Chemokines in cancer. Cytokine and Growth Factor Reviews, 2002, 13, 143-154.	7.2	311
102	Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. European Journal of Immunology, 2002, 32, 231-242.	2.9	156
103	Tumour escape from immune surveillance through dendritic cell inactivation. Seminars in Cancer Biology, 2002, 12, 33-42.	9.6	205
104	Antigen Uptake by Dendritic Cells. , 2001, 64, 369-376.		6
105	Expression of macrophage inflammatory protein-3Î±, stromal cellâ€“derived factor-1, and B-cellâ€“attracting chemokine-1 identifies the tonsil crypt as an attractive site for B cells. Blood, 2001, 97, 3992-3994.	1.4	39
106	IL-10 Induces CCR6 Expression During Langerhans Cell Development While IL-4 and IFN-Î³ Suppress It. Journal of Immunology, 2001, 167, 5594-5602.	0.8	40
107	Propagation of Human Dendritic Cells In Vitro. , 2001, 64, 257-273.		0
108	Human thymus contains IFN-Î±â€“producing CD11câ€“, myeloid CD11c+, and mature interdigitating dendritic cells. Journal of Clinical Investigation, 2001, 107, 835-844.	8.2	172

#	Article	IF	Citations
109	Human thymus contains IFN-Î±-producing CD11câ€“, myeloid CD11c+, and mature interdigitating dendritic cells. Journal of Clinical Investigation, 2001, 108, 1237-1237.	8.2	2
110	B cells. , 2001, , 255-261.		0
111	Immunobiology of Dendritic Cells. Annual Review of Immunology, 2000, 18, 767-811.	21.8	5,918
112	Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Seminars in Immunopathology, 2000, 22, 345-369.	4.0	273
113	Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms. Journal of Immunology, 2000, 165, 1992-2000.	0.8	144
114	Macrophage Inflammatory Protein 3Î± Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors. Journal of Experimental Medicine, 2000, 192, 705-718.	8.5	346
115	Up-Regulation of Macrophage Inflammatory Protein-3Î±/CCL20 and CC Chemokine Receptor 6 in Psoriasis. Journal of Immunology, 2000, 164, 6621-6632.	0.8	501
116	Langerin, a Novel C-Type Lectin Specific to Langerhans Cells, Is an Endocytic Receptor that Induces the Formation of Birbeck Granules. Immunity, 2000, 12, 71-81.	14.3	873
117	The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. European Journal of Immunology, 1999, 29, 2695-2704.	2.9	255
118	Respective involvement of TGF-Î² and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors. Journal of Leukocyte Biology, 1999, 66, 781-791.	3.3	128
119	Dendritic cells directly modulate B cell growth and differentiation. Journal of Leukocyte Biology, 1999, 66, 224-230.	3.3	129
120	Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. Journal of Leukocyte Biology, 1999, 66, 252-262.	3.3	224
121	Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites. Journal of Experimental Medicine, 1998, 188, 373-386.	8.5	1,294
122	Human Dendritic Cells Skew Isotype Switching of CD40-activated Naive B Cells towards IgA1 and IgA2. Journal of Experimental Medicine, 1997, 185, 1909-1918.	8.5	229
123	CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3Î± and Is Highly Expressed in Human Dendritic Cells. Journal of Experimental Medicine, 1997, 186, 837-844.	8.5	342
124	Dendritic Cells Enhance Growth and Differentiation of CD40-activated B Lymphocytes. Journal of Experimental Medicine, 1997, 185, 941-952.	8.5	291
125	Measles Virus Infects Human Dendritic Cells and Blocks Their Allostimulatory Properties for CD4+ T Cells. Journal of Experimental Medicine, 1997, 186, 801-812.	8.5	271
126	CD34+ Hematopoietic Progenitors From Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to Granulocyte-Macrophage Colony-Stimulating Factor Plus Tumor Necrosis Factor Î±: II. Functional Analysis. Blood, 1997, 90, 1458-1470.	1.4	394

#	Article	IF	Citations
127	Dendritic Cell Development: Multiple Pathways to Nature's Adjuvants. Stem Cells, 1997, 15, 409-419.	3.2	203
128	Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells. European Journal of Immunology, 1997, 27, 2471-2477.	2.9	91
129	Human Dendritic/Langerhans Cells Control Growth and Differentiation of CD40 Activated B Cells. Advances in Experimental Medicine and Biology, 1997, 417, 329-334.	1.6	5
130	Infection of Human Dendritic Cells by Measles Virus Induces Immune Suppression. Advances in Experimental Medicine and Biology, 1997, 417, 421-423.	1.6	9
131	CD34+ Hematopoietic Progenitors From Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to Granulocyte-Macrophage Colony-Stimulating Factor Plus Tumor Necrosis Factor Î±: II. Functional Analysis. Blood, 1997, 90, 1458-1470.	1.4	40
132	In Vitro Regulation of Dendritic Cell Development and Function. Blood Cell Biochemistry, 1996, , 263-301.	0.3	19
133	Recent advances in the study of dendritic cells and follicular dendritic cells. Trends in Immunology, 1995, 16, 2-4.	7.5	183
134	Inhibitory Effect of IL-10 on Human Langerhans Cell Antigen Presenting Function. Advances in Experimental Medicine and Biology, 1995, 378, 359-361.	1.6	3
135	Activation of Primary Allogeneic CD8+ T Cells by Dendritic Cells Generated in Vitro from CD34+ Cord Blood Progenitor Cells. Advances in Experimental Medicine and Biology, 1995, 378, 371-374.	1.6	6
136	Human Dendritic Cells Enhance Growth and Differentiation of CD40 Activated B Cells. Advances in Experimental Medicine and Biology, 1995, 378, 397-399.	1.6	6
137	Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. International Immunology, 1994, 6, 1177-1185.	4.0	185
138	Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. European Journal of Immunology, 1994, 24, 884-891.	2.9	141